论文部分内容阅读
目的观察小剂量硼替佐米联合化疗治疗复发难治或初发多发性骨髓瘤(MM)的疗效和不良反应。方法4例MM患者接受硼替佐米+环磷酰胺+地塞米松+沙利度胺治疗,每3周为一疗程。所有患者接受2~4疗程的治疗。采用EBMT疗效标准评价疗效,按国立癌症研究所的常规毒性判定标准评价不良反应。结果4例MM患者中1例接近完全缓解,3例部分缓解。不良反应有白细胞减少、血小板减少、肺部感染等。结论小剂量硼替佐米联合化疗可作为复发难治或初发MM的治疗选择。
Objective To observe the efficacy and adverse reactions of low dose bortezomib combined with chemotherapy in the treatment of relapsed or refractory or primary multiple myeloma (MM). Methods Four patients with MM received bortezomib + cyclophosphamide + dexamethasone plus thalidomide, and were given once every 3 weeks. All patients received 2 to 4 courses of treatment. EBMT curative effect was used to evaluate the curative effect. Adverse reactions were evaluated according to the routine toxicity judgment standard of National Cancer Institute. Results One of 4 MM patients was almost completely relieved and 3 patients partially relieved. Adverse reactions are leukopenia, thrombocytopenia, lung infection and so on. Conclusion Low-dose bortezomib combined with chemotherapy can be used as a treatment option for refractory or recurrent MM.